Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China

Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improves glycated hemoglobin levels and body weight in patients with type 2 diabetes (T2DM). We aim to evaluate the cost-effectiveness of once-daily oral semaglutide in comparison to placebo and injectable G...

Full description

Bibliographic Details
Main Authors: Zhen Feng, Wai Kei Tong, Xinyue Zhang, Zhijia Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
semaglutide
GLP-1 receptor agonists
type 2 diabetes
China
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1226778/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1226778/full

Similar Items